NCT06686797View on ClinicalTrials.gov

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 27, 2024

Primary Completion Date

December 22, 2025

Study Completion Date

December 22, 2025

Conditions
Healthy
Interventions
DRUG

PF-08049820

Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).

DRUG

Placebo

Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).

Trial Locations (1)

06511

RECRUITING

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06686797 - A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults | Biotech Hunter | Biotech Hunter